AstraZeneca(US:AZN) Zheng Quan Shi Bao Wang·2025-11-09 10:44Core Insights - AstraZeneca has participated in the China International Import Expo (CIIE) for eight consecutive years, showcasing its commitment to the Chinese market and announcing a new investment of approximately $136 million to expand its production capacity for inhalation aerosol products [1][2] Group 1: Investment and Expansion - AstraZeneca announced an additional investment of approximately $136 million to enhance the production capacity of inhalation aerosol products in Qingdao, aimed at better serving patients with respiratory diseases such as asthma and COPD [1] - Over the past two years, AstraZeneca has invested more than $1.8 billion in China, with the recent establishment of a new global strategic R&D center in Beijing, which is part of a broader $2.5 billion investment plan [1] Group 2: Product and Innovation - At the CIIE, AstraZeneca showcased over 40 innovative drugs developed over the past 30 years for Chinese patients and plans to accelerate the introduction of several new drugs in the next two years, covering chronic diseases, oncology, and rare diseases [1] - The company emphasized its role in transforming exhibition products into market-ready goods, contributing to the rapid development of China's healthcare industry [2] Group 3: Health Initiatives - During the CIIE, AstraZeneca hosted over 30 events focusing on chronic diseases, oncology, and rare diseases, including a new "Health Day" series aimed at strengthening the foundation of a healthy China [2] - The company highlighted the CIIE as a platform for global innovation collaboration and exchange, providing unprecedented opportunities for multinational companies to deepen their engagement in the Chinese market [2]